It was exploratory trial, trying different drug combinations for different types of cancer.
You can't depend on Clinicaltrial.gov for accurate timeline. More often than not, update time lag is signficant. Updated in Sept 2009 doesn't mean the evet actually happened in Sept 2009.
AEZS's 35 patients are the same as 38 patients in final analysis, the difference AEZS didn't include 3 patients couldn't be assessed for response.
I think the more important question is how number of 38 patients was decided, and what assumption, ie power calculation etc was made. These are important information companies should disclose.
Perifosine in phase I with different dosing regimens as single agent, found no response in CRC. Thus this could be the drug finally found the right combination for right disease setting, or the drug worked in a trial for patients that have certain hidden characteristics/inbalance that cannot be repeated in large trial. I don't think anyone knows at this point.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.